A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Olaparib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 12 Feb 2025 Status changed from recruiting to withdrawn prior to enrolment. ( Sponsor terminated due to Olaparib losing patent)
- 17 Jan 2024 Planned End Date changed from 1 Nov 2029 to 31 Dec 2029.
- 17 Jan 2024 Planned primary completion date changed from 1 Nov 2027 to 31 Dec 2027.